Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2007 Nov 7;13(41):5440-5.
doi: 10.3748/wjg.v13.i41.5440.

Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B

Fen-Yu Ren  1 , Hai Jin, Xi-Xu Piao, Feng-Shun Piao
Affiliations
Clinical Trial

Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B

Fen-Yu Ren et al. World J Gastroenterol. .

Abstract

Aim: To investigate the anti-viral mechanism of combination therapy of interferon (IFN)-alpha and ribavirin in patients with chronic hepatitis B.

Methods: Twenty patients were assigned to receive either IFN-alpha plus ribavirin (group A, n = 14) or no treatment as a control (group B, n = 6). Patients were analyzed for T-cell proliferative responses specific for hepatitis B virus (HBV)-antigen and cytokine production by peripheral blood mononuclear cells (PBMCs).

Results: Combination therapy induced HBV-antigen specific CD4+ T-cell proliferative responses in four patients (28.6%). Production of high levels of HBV-specific IFN-gamma, tumor necrosis factor (TNF)-alpha, interleukin (IL)-12 by PBMCs was found in five patients (35.7%), who showed significantly lower HBV DNA levels in serum at 12 mo after treatment ended (P = 0.038) and at 24 mo of follow-up (P = 0.004) than those without high levels of cytokine production.

Conclusion: HBV-antigen specific CD4+ T cells may directly control HBV replication and secretion of anti-viral T helper 1 (Th1) cytokines by PBMCs during combination therapy of chronic hepatitis B with ribavirin and IFN-alpha.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Abrogation of antigen-specific T-cell proliferative responses from patients 1-4 at 12 mo (bP < 0.01 vs T cell and Anti CD8+).
Figure 2
Figure 2
Cytokine production levels in PBMCs in combination therapy patients. The vertical axis represents the ratio of the mean cytokine concentration of triplicate cultures obtained in the presence of antigen to that obtained without antigen. The numbers in the horizontal lines represent the patients. A: Th1 cytokine production in PBMCs in combination therapy patients; B: Th2 cytokine production in PBMCs in combination therapy patients.
See this image and copyright information in PMC

References

    1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089–2094. - PubMed
    1. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29–60. - PubMed
    1. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993;119:312–323. - PubMed
    1. Sokal E. Drug treatment of pediatric chronic hepatitis B. Paediatr Drugs. 2002;4:361–369. - PubMed
    1. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61–68. - PubMed

Publication types

MeSH terms